注册以创建品种、
财经事件和所关注作者内容的提醒
免费注册 已有账户? 登录
Aura Biosciences Inc是一家临床阶段的生物技术公司,专注于开发病毒样药物偶联物 (VDC),这是一种用于治疗多种肿瘤适应症的新型疗法。该公司的主要VDC候选药物AU-011(belzupacap sarotalocan)由与抗癌剂结合的病毒样颗粒组成。AU-011由人乳头瘤病毒 (HPV) 衍生的类病毒颗粒(VLP)与数百个红外激光激活分子结合而成。AU-011选择性地靶向和破坏癌细胞并激活免疫系统,有可能产生持久的抗肿瘤免疫。AU-011正在开发用于眼癌,正在进行的II期剂量递增临床试验评估脉络膜黑色素瘤的一线治疗。该公司寻求在其眼部肿瘤专营权中开发AU-011,包括治疗脉络膜转移患者。此外,该公司正在开发用于治疗非肌肉浸润性膀胱癌的AU-011。
名称 | 年龄 | 任期 | 标题 |
---|---|---|---|
Rajesh Bhikhu Parekh | 63 | 2015 | Independent Director |
Karan S. Takhar | 32 | 2021 | Independent Director |
David Michael Johnson | 57 | 2021 | Independent Chairman of the Board |
John T. Schiller | - | 2021 | Member of Scientific Advisory Board |
Sapna Srivastava | 52 | 2021 | Independent Director |
Arun D. Singh | - | - | Scientific & Clinical Advisor |
Giovanni Mariggi | 37 | 2019 | Independent Director |
Elisabet de los Pinos | 49 | 2007 | Founder, CEO, President & Director |
Jay S. Duker | 64 | - | Scientific & Clinical Advisor |
Evangelos S. Gragoudas | - | - | Scientific & Clinical Advisor |
Carol L. Shields | - | - | Scientific & Clinical Advisor |
Brian Marr | - | - | Scientific & Clinical Advisor |
Richard Carvajal | - | - | Scientific & Clinical Advisor |
Antony Mattessich | 56 | 2021 | Independent Director |
Isaac Yi Kim | - | 2021 | Member of Scientific Advisory Board |
Seth P. Lerner | - | 2021 | Member of Scientific Advisory Board |
Gary Steinberg | - | 2024 | Member of Scientific Advisory Board |
Neal Shore | - | 2023 | Member of Scientific Advisory Board |
Andrea Apolo | - | 2021 | Member of Scientific Advisory Board |
Max Kates | - | 2023 | Member of Scientific Advisory Board |
确定屏蔽%USER_NAME%?
如果屏蔽,您和%USER_NAME%都无法看到相互在Investing.com上发布的信息。
%USER_NAME%已成功添加至屏蔽列表
由于您刚刚取消屏蔽此人,因此必须等待48小时才能重新屏蔽。
您举报该评论的原因为:
谢谢您!
您的举报将会被发送到管理员进行审核